Genmab — November 2025

[transalp]

Go weekend..

[E_L]

Merus SCHEDULE 14A

NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS OF MERUS N.V. TO BE HELD https://www.sec.gov/Archives/edgar/data/1651311/000119312525260837/d54485dprem14a.htm

[Peter_Panik]

Handelsbanken hæver kursmål fra 2000 til 2000

[Peter_Panik]

ja til 2200

[ProinvestorNEWS]

Genmab får hævet kursmålet til 2200 kr. hos svensk storbank https://proinvestor.com/investornyt/1378090/genmab-far-haevet-kursmalet-til-2200-kr-hos-svensk-storbank

[Plimsoller]

Vi må ikke håbe at det er 2200 svenske kroner

[E_L]

GEN1059 and GEN1042 still in the Biontech pipeline at Q3 25...

[E_L]

ASH 2025 . enjoy.
https://submit.hematology.org/program?query=epcoritamab&is_sponsored=0&is_highlighted=0&is_on_demand=0&streaming_allowed=0&filterbox=false&legendbox=false&timezone=false&day=2025-12-05&pre_filter=All&viewType=list&segment=presentations&segmentname=Presentations&upcoming=0&order=starts_at

[E_L]

Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American Society of Hematology (ASH) Annual Meeting https://ir.genmab.com/news-releases/news-release-details/genmab-showcase-latest-blood-cancer-treatment-advancements-2025

[Plimsoller]

That's a long list E L Any chance of a late breaking abstract?

[Solsen]

7 orale præsentationer er flot. Biontech afholder en R&D update den 11. november, som kan være interessant som Genmab investor.

[E_L]

was this still not enough Plimsoller??? there is always a chance, but only very few LBA's , i think last year only 6 or so

[E_L]

i think the FL abstracts are important, in combination with the potential FDA approval late this month

[Plimsoller]

More wants more

[Plimsoller]

Thank you

[E_L]

[E_L]

the FDA reversed its previous position on a sBLA for UniQure and the stock drops 56%. not sure if that is what drives biotech sentiment this US morning but not a good bio-start for november...

[lahn1]

Er det bare mig eller bliver real world data på Epco og Glofi udlagt negativt. Man kan jo ikke sammenligne trials hvor pts skal være CD20 +ve med real world data i 3L hvor 80% af pts har tabt CD20 expression. Nogen som har et bud på om dette vil ændre peak sales på Epco ? Søg på Epcoritamab på X og jeg syntes budskabet er epco/Glofi præsterer dårligere i real life end i trials.

[npo]

My two cents : Whereas writer – and I trust other investors - appreciate in-put with a technical background from professionals in this forum. Regrettably, however, due to use of acronyms and abbreviations in-put often becomes so technical it often comes across gobbledygook – incomprehensible to ordinary mortals (investors). Use of “simpler” terms and less acronyms etc. could enable/attract more investors to read and follow progress and in the process be attracted to support Genmab.

[Bella1]

Tak, npo